DE602004006379D1 - Benzthiazol-3 oxide zur behandlung von proliferativen störungen - Google Patents

Benzthiazol-3 oxide zur behandlung von proliferativen störungen

Info

Publication number
DE602004006379D1
DE602004006379D1 DE602004006379T DE602004006379T DE602004006379D1 DE 602004006379 D1 DE602004006379 D1 DE 602004006379D1 DE 602004006379 T DE602004006379 T DE 602004006379T DE 602004006379 T DE602004006379 T DE 602004006379T DE 602004006379 D1 DE602004006379 D1 DE 602004006379D1
Authority
DE
Germany
Prior art keywords
sup
sub
nhr
saturated
ring system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004006379T
Other languages
English (en)
Other versions
DE602004006379T2 (de
Inventor
Campbell Mcinnes
Christopher Meades
Mokdad Mezna
Peter Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of DE602004006379D1 publication Critical patent/DE602004006379D1/de
Application granted granted Critical
Publication of DE602004006379T2 publication Critical patent/DE602004006379T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Lubricants (AREA)
DE602004006379T 2003-01-30 2004-01-27 Benzthiazol-3 oxide zur behandlung von proliferativen störungen Expired - Fee Related DE602004006379T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302220 2003-01-30
GBGB0302220.9A GB0302220D0 (en) 2003-01-30 2003-01-30 Use
PCT/GB2004/000327 WO2004067000A1 (en) 2003-01-30 2004-01-27 Benzthiazole-3 oxides useful for the treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
DE602004006379D1 true DE602004006379D1 (de) 2007-06-21
DE602004006379T2 DE602004006379T2 (de) 2008-01-10

Family

ID=9952174

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004006379T Expired - Fee Related DE602004006379T2 (de) 2003-01-30 2004-01-27 Benzthiazol-3 oxide zur behandlung von proliferativen störungen

Country Status (7)

Country Link
US (1) US20060040997A1 (de)
EP (1) EP1589967B1 (de)
JP (1) JP2006518361A (de)
AT (1) ATE361749T1 (de)
DE (1) DE602004006379T2 (de)
GB (1) GB0302220D0 (de)
WO (1) WO2004067000A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
US7245789B2 (en) 2002-10-07 2007-07-17 Vascular Imaging Corporation Systems and methods for minimally-invasive optical-acoustic imaging
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
ES2585110T3 (es) 2007-09-28 2016-10-03 Cyclacel Limited Derivados de pirimidina como inhibidores de proteína cinasa
WO2010039950A1 (en) 2008-10-02 2010-04-08 Eberle Michael J Optical ultrasound receiver
JP2012512223A (ja) 2008-12-18 2012-05-31 エフ．ホフマン−ラ ロシュ アーゲー チアゾリル−ベンズイミダゾール類
FR2967672B1 (fr) 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
KR102081417B1 (ko) * 2018-11-23 2020-02-25 주식회사 이뮤니스바이오 Ｂｔｏ―１의 ｎｋ 세포 증식 용도
WO2021032959A1 (en) 2019-08-16 2021-02-25 Cyclacel Limited Crystalline forms of pyrimidino diazepine derivative
CA3145287A1 (en) 2019-08-16 2021-02-25 Benjamin Skead Process for the preparation of a pyrimidino-diazepine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1904653A1 (de) * 1969-01-31 1970-08-13 Bayer Ag Substituierte Benzthiazol-N-oxide
DE2013434A1 (en) * 1970-03-20 1971-10-07 Farbenfabriken Bayer Ag, 5090 Lever Kusen Benzothiazole 3-oxides as concrementinhibitors
DE3835660A1 (de) * 1988-03-25 1989-10-12 Bayer Ag 7-substituierte 2-carbonamido-benzthiazol-3-oxide
US6492389B1 (en) * 1998-07-21 2002-12-10 Thomas Jefferson University Small molecule inhibitors of BCL-2 proteins

Also Published As

Publication number Publication date
EP1589967A1 (de) 2005-11-02
WO2004067000A1 (en) 2004-08-12
ATE361749T1 (de) 2007-06-15
JP2006518361A (ja) 2006-08-10
GB0302220D0 (en) 2003-03-05
EP1589967B1 (de) 2007-05-09
US20060040997A1 (en) 2006-02-23
DE602004006379T2 (de) 2008-01-10

Similar Documents

Publication Publication Date Title
DE602004006379D1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
CY1107509T1 (el) Αμινοθειαζολες ως αναστολεις κυκλινη - εξαρτωμενων κινασεων
HUP0104364A2 (hu) Pirrolidinszármazékok, CCR-3 receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények
DE602004031037D1 (de) Heterocyclische inhibitoren von mek
HUP9903762A2 (hu) Embólia, trombózis és arterioszklerózis megelőzésére vagy kezelésére alkalmas gyűrűs aminszármazékok és alkalmazásuk
EA199901015A1 (ru) 4"-замещенные производные 9-деоксо-9а-а3а-9а-гомоэритромицина а
HUP0100388A2 (hu) Készítmények és eljárások csontritkulás kezelésére és a koleszterinszint csökkentésére
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200100623A1 (ru) Кетолидные антибиотики
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
EA200100983A1 (ru) Производные 13-метилэритромицина
PE20001297A1 (es) Antibioticos cetolidos carbamato y carbazato
MY136686A (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production
HUP0303514A2 (hu) AlfavBéta6 integrin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
IS2387B (is) Æxliseyðandi efni
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
EA200400896A1 (ru) Терапевтические акридоновые и акридиновые соединения
IE892596L (en) Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
DE69330601D1 (de) Serotoninergische ergolin derivate
DE60019157D1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee